Deutsch
Deutschland
Anmelden
Tipp von eurobuch.com
Ähnliche Bücher
Weitere, andere Bücher, die diesem Buch sehr ähnlich sein könnten:
Buch verkaufen
Anbieter, die das Buch mit der ISBN 9780387894447 ankaufen:
Suchtools
Buchtipps
Aktuelles
FILTER
- 0 Ergebnisse
Kleinster Preis: 145,88 €, größter Preis: 219,92 €, Mittelwert: 188,67 €
Drug Resistance in Cancer Cells - Kapil Mehta
Vergriffenes Buch, derzeit bei uns nicht verfügbar.
(*)
Kapil Mehta:
Drug Resistance in Cancer Cells - neues Buch

1, ISBN: 9780387894447

[ED: Buch], [PU: Springer-Verlag GmbH], Neuware - It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt - in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de nition - multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies - its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors., DE, [SC: 0.00], Neuware, gewerbliches Angebot, 234x155x22 mm, 363, [GW: 712g], offene Rechnung (Vorkasse vorbehalten), PayPal, Kreditkarte, Banküberweisung, Internationaler Versand

Neues Buch Booklooker.de
Buchhandlung - Bides GbR
Versandkosten:Versandkostenfrei, Versand nach Deutschland. (EUR 0.00)
Details...
(*) Derzeit vergriffen bedeutet, dass dieser Titel momentan auf keiner der angeschlossenen Plattform verfügbar ist.
Drug Resistance in Cancer Cells - Kapil Mehta
Vergriffenes Buch, derzeit bei uns nicht verfügbar.
(*)
Kapil Mehta:
Drug Resistance in Cancer Cells - neues Buch

1, ISBN: 9780387894447

[ED: Buch], [PU: Springer-Verlag GmbH], Neuware - It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt - in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de nition - multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies - its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors., DE, [SC: 0.00], Neuware, gewerbliches Angebot, FixedPrice, 363, [GW: 712g], offene Rechnung (Vorkasse vorbehalten), PayPal, Banküberweisung

Neues Buch Booklooker.de
Buchhandlung Kühn GmbH
Versandkosten:Versandkostenfrei, Versand nach Deutschland. (EUR 0.00)
Details...
(*) Derzeit vergriffen bedeutet, dass dieser Titel momentan auf keiner der angeschlossenen Plattform verfügbar ist.
Drug Resistance in Cancer Cells - Kapil Mehta
Vergriffenes Buch, derzeit bei uns nicht verfügbar.
(*)
Kapil Mehta:
Drug Resistance in Cancer Cells - neues Buch

1, ISBN: 9780387894447

[ED: Buch], [PU: Springer-Verlag GmbH], Neuware - It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt - in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de nition - multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies - its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors., DE, [SC: 0.00], Neuware, gewerbliches Angebot, 234x155x22 mm, 363, [GW: 712g], PayPal, Banküberweisung, Internationaler Versand

Neues Buch Booklooker.de
buchversandmimpf2000
Versandkosten:Versandkostenfrei, Versand nach Deutschland. (EUR 0.00)
Details...
(*) Derzeit vergriffen bedeutet, dass dieser Titel momentan auf keiner der angeschlossenen Plattform verfügbar ist.
Drug Resistance in Cancer Cells
Vergriffenes Buch, derzeit bei uns nicht verfügbar.
(*)
Drug Resistance in Cancer Cells - neues Buch

ISBN: 9780387894447

ID: 978038789444

The inability of cancer drugs to destroy metastatic tumors is the major reason why cancer therapy fails. Even though the process of drug design has become exceedingly sophisticated in recent years, there is not a single drug available that is 100% effective against metastatic cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic/genetic differences in tumors, even those from tissue of origin. Although it is a generally accepted fact that the majority of cancers arise from a single precursor cell, it is naïve to consider that tumor is a collection of genetically identical cells. Genetic instability and accumulation of mutations are important hallmarks of cancer cells. This means that dividing cancer cells are able to acquire genetic and epigenetic changes that will favor their malignant phenotype. In view of this, it is fair to say that the cells in a given tumor may be similar but not identical. Therefore, when treated with a drug, the sensitive cells in a tumor succumb to the toxic effects of the drug, and resistant cells continue to survive and multiply. The tumor, which re-grows from these residual resistant cells, is not sensitive to the original drug. Books, Health and Well Being, Drug Resistance in Cancer Cells Books>Health and Well Being, Springer New York

Neues Buch Indigo.ca
new Free shipping on orders above $25. Versandkosten:zzgl. Versandkosten.
Details...
(*) Derzeit vergriffen bedeutet, dass dieser Titel momentan auf keiner der angeschlossenen Plattform verfügbar ist.
Drug Resistance in Cancer Cells - Mehta, Kapil / Siddik, Zahid H.
Vergriffenes Buch, derzeit bei uns nicht verfügbar.
(*)
Mehta, Kapil / Siddik, Zahid H.:
Drug Resistance in Cancer Cells - gebrauchtes Buch

ISBN: 9780387894447

ID: 1183097

The inability of cancer drugs to destroy metastatic tumors is the major reason why cancer therapy fails. Even though the process of drug design has become exceedingly sophisticated in recent years, there is not a single drug available that is 100% effective against metastatic cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic/genetic differences in tumors, even those from tissue of origin. Although it is a generally accepted fact that the majority of cancers arise from a single precursor cell, it is naAve to consider that tumor is a collection of genetically identical cells. Genetic instability and accumulation of mutations are important hallmarks of cancer cells. This means that dividing cancer cells are able to acquire genetic and epigenetic changes that will favor their malignant phenotype. In view of this, it is fair to say that the cells in a given tumor may be similar but not identical. Therefore, when treated with a drug, the sensitive cells in a tumor succumb to the toxic effects of the drug, and resistant cells continue to survive and multiply. The tumor, which re-grows from these residual resistant cells, is not sensitive to the original drug. Drug Resistance in Cancer Cells Mehta, Kapil / Siddik, Zahid H., Springer

gebrauchtes bzw. antiquarisches Buch Betterworldbooks.com
Versandkosten:zzgl. Versandkosten.
Details...
(*) Derzeit vergriffen bedeutet, dass dieser Titel momentan auf keiner der angeschlossenen Plattform verfügbar ist.

Details zum Buch
Drug Resistance in Cancer Cells

It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt – in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de?nition – multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies – its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de?nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by m

Detailangaben zum Buch - Drug Resistance in Cancer Cells


EAN (ISBN-13): 9780387894447
ISBN (ISBN-10): 0387894446
Gebundene Ausgabe
Erscheinungsjahr: 2009
Herausgeber: Springer-Verlag GmbH
363 Seiten
Gewicht: 0,712 kg
Sprache: eng/Englisch

Buch in der Datenbank seit 09.08.2008 14:55:25
Buch zuletzt gefunden am 05.12.2017 10:57:44
ISBN/EAN: 9780387894447

ISBN - alternative Schreibweisen:
0-387-89444-6, 978-0-387-89444-7


< zum Archiv...
Benachbarte Bücher